Progesterone Use in Pregnancy with Subchorionic Hematoma – Guideline Recommendations
Guideline Stance on Progesterone for Subchorionic Hematoma
- The American College of Obstetricians and Gynecologists (ACOG) does not recommend progesterone supplementation as a primary treatment for subchorionic hematoma; current evidence‑based guidelines focus on preterm‑birth prevention rather than hematoma management. 1
Established Indications for Progesterone (Preterm‑Birth Prevention)
- Prior spontaneous preterm birth – ACOG recommends 17‑hydroxyprogesterone caproate (17P) 250 mg intramuscularly once weekly, initiated between 16–20 weeks’ gestation and continued until 36 weeks. This is a guideline‑strong recommendation for preterm‑birth risk reduction, not for hematoma treatment. 1
- Short cervical length (≤20 mm) without prior preterm birth – ACOG recommends vaginal progesterone either as a 90‑mg gel or a 200‑mg suppository administered daily from the time of diagnosis until 36 weeks’ gestation. This recommendation is supported by moderate‑to‑strong evidence for preventing preterm delivery. 1
- Routine pregnancies without these risk factors – ACOG states that there is no evidence supporting routine progesterone use in uncomplicated pregnancies. 1
Management Algorithms for Patients with Subchorionic Hematoma
- Isolated subchorionic hematoma (no prior preterm birth, normal cervical length) – Standard obstetric care per ACOG guidelines is advised; progesterone is not indicated. 1
- Subchorionic hematoma + prior spontaneous preterm birth – Initiate 17P 250 mg IM weekly at 16–20 weeks (for preterm‑birth prevention; not intended to treat the hematoma). 1
- Subchorionic hematoma + short cervical length (≤20 mm) diagnosed ≤24 weeks – Add vaginal progesterone (90‑mg gel or 200‑mg suppository daily) regardless of hematoma status, following ACOG preterm‑birth prevention protocol. 1
Contraindications and Situations Where Progesterone Is Not Indicated
- Progesterone should not be used in multiple gestations, active preterm labor, or preterm premature rupture of membranes, as there is no evidence of benefit for these conditions. 1
- Injectable 17P must not be substituted with oral or vaginal progesterone formulations; each has distinct indications and dosing regimens. 1
Note: All statements above are derived from ACOG guideline citations (1, 2, 3); the evidence strength ranges from strong guideline recommendations (for indicated uses) to lack of evidence (for non‑indicated uses).
Progesterone Dosing for Pregnancy with Subchorionic Hemorrhage
Evidence-Based Recommendations
- The American College of Obstetricians and Gynecologists recommends oral progesterone 400 mg daily for preventing preterm birth, with some evidence suggesting its benefit, although with less robust evidence than vaginal administration 4, 5
Duration of Treatment
- The American College of Obstetricians and Gynecologists suggests that progesterone therapy typically continues until 34-37 weeks of gestation for preterm birth prevention 4, 6